IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• IDEXX has an average analyst rating of "Moderate Buy" (7 buys, 3 holds) with a 12‑month average target of about $772, although several firms recently trimmed price targets and downgraded ratings.
• The company beat Q4 estimates with $3.08 EPS vs. $2.93 consensus and $1.09B revenue (up 14.3% year‑over‑year), and issued FY2026 EPS guidance of $14.29–$14.80.
• Insiders have been net sellers recently—about 45,957 shares (~$29.9M) sold in the last 90 days—while institutional investors own roughly 87.8% of the stock.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $772.2222.

Several research firms have recently weighed in on IDXX. UBS Group lowered their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 3rd. Weiss Ratings lowered IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, January 29th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research note on Monday, February 9th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th.

IDEXX Laboratories Stock Performance

IDXX stock opened at $563.00 on Monday. IDEXX Laboratories has a 1-year low of $375.05 and a 1-year high of $769.98. The firm has a market cap of $44.72 billion, a P/E ratio of 43.08, a P/E/G ratio of 3.42 and a beta of 1.72. The business's 50 day moving average is $607.41 and its 200-day moving average is $656.92. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the company posted $2.53 EPS. The company's revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts anticipate that IDEXX Laboratories will post 11.93 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. This represents a 29.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,957 shares of company stock worth $29,862,109 over the last 90 days. Company insiders own 0.79% of the company's stock.

Institutional Investors Weigh In On IDEXX Laboratories

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in IDEXX Laboratories by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company's stock worth $6,364,638,000 after acquiring an additional 86,040 shares during the last quarter. Elyxium Wealth LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $3,666,459,000. State Street Corp grew its position in IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock worth $2,473,817,000 after acquiring an additional 138,956 shares during the last quarter. J. Stern & Co. LLP grew its position in IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after acquiring an additional 2,642,200 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock worth $1,749,380,000 after acquiring an additional 86,263 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.